GO:0010613 positive regulation of cardiac muscle hypertrophy: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010613 describes any process that increases the rate, frequency, or extent of cardiac muscle hypertrophy, defined as enlargement of the heart due to increased size (not length) of individual cardiac muscle fibers without cell division.
• Cardiac hypertrophy is broadly classified as physiological (adaptive, reversible) or pathological (maladaptive, often leading to heart failure), and both are driven by distinct but overlapping signaling networks.
• Key molecular drivers include the DYRK1B-STAT3 axis, which impairs mitochondrial bioenergetics, and long noncoding RNAs such as LincRNA-p21, whose inhibition protects against hypertrophy.
• Metabolic and inflammatory pathways, including histamine N-methyltransferase upregulation, acid sphingomyelinase-mediated mitochondrial calcium disruption, and NLRP3/IL1β signaling, contribute to hypertrophy and heart failure.
• Autophagy and mitophagy are essential for maintaining cardiac function under stress; their dysregulation exacerbates diabetic cardiomyopathy and hypertrophy.
• Clusterin is dynamically regulated in the heart and plasma after transverse aortic constriction, highlighting its potential as a biomarker and therapeutic target in hypertrophy.
Description
Cardiac muscle hypertrophy is an adaptive response of the heart to increased workload, neurohormonal stress, or injury, characterized by an increase in the size of individual cardiomyocytes without cell division. The Gene Ontology term GO:0010613, positive regulation of cardiac muscle hypertrophy, encompasses any process that increases the rate, frequency, or extent of this enlargement. This term is critical for understanding both physiological cardiac growth, such as that induced by exercise, and pathological hypertrophy, which often progresses to heart failure. Researchers study GO:0010613 to identify molecular drivers and therapeutic targets that can promote beneficial adaptation or prevent maladaptive remodeling. Recent studies have uncovered diverse regulators, including the DYRK1B-STAT3 signaling axis that impairs mitochondrial bioenergetics, the long noncoding RNA LincRNA-p21 whose inhibition protects against hypertrophy, and metabolic enzymes such as histamine N-methyltransferase. These findings underscore the complexity of positive regulation and the need for precise experimental models. This article integrates authoritative GO definitions with verified PubMed literature to provide a research-grade overview of GO:0010613, covering its mechanisms, key genes, disease relevance, and state-of-the-art methods for investigation.
positive regulation of cardiac muscle hypertrophy At A Glance
| GO ID | GO:0010613 |
|---|---|
| GO term | positive regulation of cardiac muscle hypertrophy |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate, frequency, or extent of cardiac muscle hypertrophy, characterized by enlarged cardiomyocytes without cell division |
| Definition source | QuickGO |
| Related processes | Pathological and physiological cardiac hypertrophy, heart failure, diabetic cardiomyopathy |
| Key signaling pathways | DYRK1B-STAT3, LincRNA-p21, histamine N-methyltransferase, acid sphingomyelinase, mitophagy, NLRP3/IL1β |
What Is GO:0010613?
GO:0010613, positive regulation of cardiac muscle hypertrophy, is defined as any biological process that increases the rate, frequency, or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division. In simpler terms, it covers the molecular and cellular events that drive heart muscle cells to grow larger in cross-sectional area, a hallmark of hypertrophic remodeling. This term is a child of positive regulation of cardiac muscle hypertrophy and is distinct from processes that regulate cell proliferation or hyperplasia. It includes signaling cascades, transcriptional programs, and metabolic adaptations that promote cardiomyocyte growth in response to stressors such as pressure overload, neurohormonal activation, or exercise.
Why Is positive regulation of cardiac muscle hypertrophy Important in Cell Biology?
GO:0010613 is essential for understanding how the heart adapts to stress and injury. Pathological cardiac hypertrophy is a major risk factor for heart failure, arrhythmias, and sudden cardiac death, affecting millions worldwide. Deciphering the positive regulators of hypertrophy can reveal therapeutic targets to prevent or reverse maladaptive remodeling. Moreover, physiological hypertrophy, such as that induced by exercise, is beneficial and cardioprotective, so distinguishing between the two is crucial for developing safe interventions. The term also intersects with metabolic, inflammatory, and mitochondrial pathways, making it a hub for interdisciplinary research [2,4,5,6,7].
• Pathological hypertrophy is a leading precursor to heart failure, a global health burden with high morbidity and mortality.
• Physiological hypertrophy improves cardiac function and is associated with reduced cardiovascular risk.
• DYRK1B-STAT3 signaling drives hypertrophy and heart failure by impairing mitochondrial bioenergetics, offering a druggable target.
• LincRNA-p21 inhibition protects against cardiac hypertrophy, highlighting noncoding RNA-based therapeutic strategies.
• Histamine N-methyltransferase upregulation is linked to cardiac hypertrophy and heart failure, suggesting metabolic regulation.
• Acid sphingomyelinase promotes diabetic cardiomyopathy via mitochondrial calcium disruption, connecting lipid metabolism to hypertrophy.
• Mitophagy is essential for maintaining cardiac function during high-fat diet-induced diabetic cardiomyopathy.
• Clusterin regulation after transverse aortic constriction may serve as a biomarker for hypertrophic remodeling.
• Inflammatory pathways such as NLRP3/IL1β contribute to macrophage-mediated injury after myocardial infarction, influencing hypertrophy.
• Understanding positive regulation enables the development of precision therapies that target specific molecular drivers [1,2,3].
What Happens During positive regulation of cardiac muscle hypertrophy?
Initiation by Mechanical and Neurohormonal Stress
In simple terms: The heart senses increased workload or stress hormones and starts a growth program.
Positive regulation of cardiac muscle hypertrophy is initiated by mechanical stretch, neurohormonal factors (e.g., angiotensin II, endothelin-1), and cytokines that activate membrane receptors and mechanosensors. These signals converge on intracellular kinases such as MAPKs, PI3K/Akt, and calcineurin-NFAT, which transduce hypertrophic cues to the nucleus. The DYRK1B-STAT3 axis has been identified as a critical driver that impairs mitochondrial bioenergetics, linking stress signaling to metabolic dysfunction.
Transcriptional and Epigenetic Reprogramming
In simple terms: The cell switches on a set of genes that make heart muscle cells grow bigger.
Activated transcription factors, including NFAT, MEF2, and GATA4, induce a fetal gene program characterized by upregulation of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and beta-myosin heavy chain. Long noncoding RNAs such as LincRNA-p21 modulate this program; its inhibition protects against hypertrophy, indicating a regulatory role. Epigenetic modifications, including histone acetylation and DNA methylation, also contribute to sustained hypertrophic gene expression.
Metabolic and Mitochondrial Adaptations
In simple terms: The heart changes how it makes energy to support its increased size.
Hypertrophic cardiomyocytes shift from fatty acid oxidation to glucose metabolism, and mitochondrial function is often compromised. DYRK1B-STAT3 signaling impairs mitochondrial bioenergetics, contributing to heart failure. Acid sphingomyelinase disrupts mitochondrial calcium homeostasis, promoting diabetic cardiomyopathy. Mitophagy, the selective removal of damaged mitochondria, is essential for maintaining cardiac function under stress, as shown in high-fat diet-induced diabetic cardiomyopathy.
Inflammatory and Immune Modulation
In simple terms: Immune cells and inflammation can either help or harm the growing heart.
Macrophage-mediated inflammation following myocardial infarction involves the NLRP3/IL1β pathway, which can exacerbate hypertrophy and heart failure. Coenzyme Q10 mitigates this inflammatory response, suggesting a therapeutic avenue. Histamine N-methyltransferase upregulation is associated with cardiac hypertrophy and heart failure, linking histamine metabolism to inflammatory processes. Clusterin, a chaperone-like protein, is regulated in the heart and plasma after transverse aortic constriction, potentially modulating stress responses.
Structural Remodeling and Cardiomyocyte Growth
In simple terms: Heart muscle cells physically enlarge and the heart wall thickens.
The culmination of positive regulation is an increase in cardiomyocyte cross-sectional area, sarcomeric organization, and interstitial fibrosis. This structural remodeling initially normalizes wall stress but eventually leads to diastolic and systolic dysfunction. The interplay between growth signals, metabolic stress, and inflammation determines whether hypertrophy remains adaptive or transitions to heart failure [1,2,5].
Key Genes Involved in GO:0010613 positive regulation of cardiac muscle hypertrophy
The following genes and proteins are experimentally validated regulators or effectors of positive regulation of cardiac muscle hypertrophy (GO:0010613), based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DYRK1B | Kinase that activates STAT3, impairs mitochondrial bioenergetics | Drives cardiac hypertrophy and heart failure; therapeutic target |
| STAT3 | Transcription factor downstream of DYRK1B | Mediates hypertrophic gene expression and mitochondrial dysfunction |
| LincRNA-p21 | Long noncoding RNA that promotes hypertrophy | Inhibition protects against cardiac hypertrophy |
| NLRP3 | Inflammasome component | Mediates macrophage inflammation after myocardial infarction |
| IL1β | Pro-inflammatory cytokine | Contributes to hypertrophy and heart failure |
| HNMT | Histamine N-methyltransferase, metabolizes histamine | Upregulation associated with cardiac hypertrophy and heart failure |
| SMPD1 | Acid sphingomyelinase, produces ceramide | Promotes diabetic cardiomyopathy via mitochondrial calcium disruption |
| CLU | Clusterin, chaperone-like protein | Regulated in heart and plasma after transverse aortic constriction |
| ANP (NPPA) | Natriuretic peptide | Fetal gene marker of hypertrophy |
| BNP (NPPB) | Natriuretic peptide | Fetal gene marker and biomarker of hypertrophy |
| MYH7 | Beta-myosin heavy chain | Fetal gene upregulated in hypertrophy |
| NFAT | Transcription factor | Drives hypertrophic gene program |
| MEF2 | Transcription factor | Regulates cardiac growth and remodeling |
| GATA4 | Transcription factor | Essential for cardiac development and hypertrophy |
| PI3K/Akt | Signaling pathway | Promotes physiological and pathological hypertrophy |
| MAPK | Mitogen-activated protein kinase | Transduces hypertrophic stress signals |
| Calcineurin | Phosphatase | Activates NFAT in pathological hypertrophy |
| mTOR | Kinase | Regulates protein synthesis and cell growth in hypertrophy |
How Is positive regulation of cardiac muscle hypertrophy Regulated?
Positive regulation of cardiac muscle hypertrophy is controlled by a multilayered network of signaling pathways, transcription factors, and noncoding RNAs. The DYRK1B-STAT3 axis directly promotes hypertrophy while impairing mitochondrial bioenergetics, and its inhibition may be therapeutic. LincRNA-p21 acts as a positive regulator; its therapeutic inhibition protects against hypertrophy. Metabolic enzymes such as histamine N-methyltransferase are upregulated in hypertrophy and heart failure, suggesting a role in disease progression. Acid sphingomyelinase disrupts mitochondrial calcium homeostasis, contributing to diabetic cardiomyopathy. Mitophagy is essential for maintaining cardiac function under stress, and its dysregulation exacerbates hypertrophy. Inflammatory pathways, including NLRP3/IL1β, modulate the hypertrophic response after myocardial infarction. Clusterin is dynamically regulated after pressure overload, potentially serving as a feedback regulator. These diverse mechanisms highlight the complexity of positive regulation and the need for integrated experimental approaches.
positive regulation of cardiac muscle hypertrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DYRK1B | Heart failure, mitochondrial dysfunction | Cardiac-specific knockout or overexpression in mice |
| LincRNA-p21 | Cardiac hypertrophy | Knockout or antisense oligonucleotide inhibition in hypertrophy models |
| SMPD1 | Diabetic cardiomyopathy | Cardiomyocyte-specific knockout or pharmacological inhibition |
| NLRP3 | Myocardial infarction, inflammation | NLRP3 knockout mice or inflammasome inhibitors |
| CLU | Hypertrophic remodeling | Clusterin knockout or overexpression after TAC |
Heart Failure
Pathological cardiac hypertrophy is a major antecedent of heart failure. DYRK1B-STAT3 signaling drives hypertrophy and heart failure by impairing mitochondrial bioenergetics, and targeting this axis may prevent disease progression. Histamine N-methyltransferase upregulation is also associated with heart failure, linking metabolic dysregulation to cardiac decompensation.
Diabetic Cardiomyopathy
Diabetes increases the risk of cardiomyopathy, partly through acid sphingomyelinase-mediated disruption of mitochondrial calcium homeostasis. Mitophagy is essential for maintaining cardiac function during high-fat diet-induced diabetic cardiomyopathy, and its impairment exacerbates hypertrophy and dysfunction.
Myocardial Infarction and Inflammation
Following myocardial infarction, macrophage-mediated inflammation via the NLRP3/IL1β pathway contributes to adverse remodeling and hypertrophy. Coenzyme Q10 mitigates this inflammatory response, suggesting a potential adjunct therapy.
Hypertrophic Remodeling and Biomarkers
Clusterin is regulated in the heart and plasma after transverse aortic constriction, indicating its potential as a biomarker for hypertrophic remodeling and a target for modulating stress responses. LincRNA-p21 inhibition protects against hypertrophy, offering a novel therapeutic strategy.
From positive regulation of cardiac muscle hypertrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive pathological hypertrophy? | Cardiac-specific knockout or overexpression in mouse transverse aortic constriction (TAC) model [2,3,8] |
| Does a point mutation in gene Y alter hypertrophic signaling? | Knock-in mouse with patient-derived mutation |
| Can a tagged protein reveal localization during hypertrophy? | Tagged knock-in (e.g., GFP) in cardiomyocytes |
| Is gene Z required for physiological hypertrophy? | Inducible cardiomyocyte-specific knockout with exercise training |
| Does noncoding RNA regulate hypertrophy? | LincRNA knockout or overexpression in TAC model |
| Does metabolic enzyme modulation affect hypertrophy? | Pharmacological inhibition or genetic deletion in diabetic cardiomyopathy models [5,6] |
How to Study the positive regulation of cardiac muscle hypertrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Identify hypertrophic gene programs and noncoding RNAs |
| ChIP-seq | Transcription factor binding and histone modifications | Map regulatory elements in hypertrophy |
| Proteomics | Protein abundance and modifications | Quantify sarcomeric and mitochondrial proteins |
| Metabolomics | Metabolite levels | Assess metabolic shifts in hypertrophy |
| Echocardiography | Cardiac structure and function | Evaluate hypertrophy in mouse models [2,8] |
| Confocal microscopy | Cardiomyocyte size and sarcomere organization | Measure cellular hypertrophy in vitro and ex vivo |
| Mitochondrial function assays | Oxygen consumption, calcium handling | Assess bioenergetics and calcium homeostasis [2,6] |
| CRISPR/Cas9 editing | Gene knockout, knock-in, overexpression | Establish causal roles of candidate genes [2,3] |
Transcriptomic and Epigenomic Profiling
RNA-seq and ChIP-seq are used to identify differentially expressed genes and regulatory elements during hypertrophy. For example, LincRNA-p21 was identified as a hypertrophy regulator through transcriptomic analysis. ATAC-seq can reveal chromatin accessibility changes that accompany transcriptional reprogramming.
Proteomic and Metabolomic Analyses
Mass spectrometry-based proteomics quantifies changes in sarcomeric, mitochondrial, and signaling proteins. Metabolomics can detect shifts in substrate utilization, such as the switch from fatty acid oxidation to glycolysis. These methods help link DYRK1B-STAT3 signaling to mitochondrial bioenergetics.
Imaging and Functional Assessment
Echocardiography measures wall thickness and chamber dimensions in animal models. Confocal microscopy of isolated cardiomyocytes assesses cell size and sarcomere organization. Mitochondrial function can be evaluated using live-cell imaging of calcium and membrane potential.
Genetic and Pharmacological Perturbation
CRISPR/Cas9-mediated knockout, knock-in, and overexpression in cell lines and mouse models are essential to establish causality. For instance, DYRK1B inhibition or knockout attenuates hypertrophy. Pharmacological agents like coenzyme Q10 can modulate inflammatory pathways.
How CRISPR Can Be Used to Study GO:0010613 positive regulation of cardiac muscle hypertrophy
Knockout
CRISPR/Cas9-mediated knockout is used to delete candidate genes in cardiomyocytes or mouse models to determine if they are required for positive regulation of cardiac muscle hypertrophy. For example, knockout of DYRK1B attenuates hypertrophy and improves mitochondrial function. Knockout of LincRNA-p21 reduces hypertrophy, confirming its positive regulatory role.
Point Mutation
Point mutations can be introduced to model human variants or to abrogate specific phosphorylation sites. For instance, mutating the STAT3 phosphorylation site can prevent DYRK1B-mediated activation. Such models help dissect signaling mechanisms without confounding effects of complete gene deletion.
Knock-in
Knock-in of tagged proteins (e.g., GFP, FLAG) allows visualization and immunoprecipitation of endogenous proteins during hypertrophy. This approach can reveal dynamic localization of clusterin after transverse aortic constriction. Knock-in of patient-derived mutations can also model inherited cardiomyopathies.
Overexpression
Overexpression of candidate genes via transgenic or viral vectors can test sufficiency in driving hypertrophy. For example, overexpression of histamine N-methyltransferase exacerbates hypertrophy and heart failure. Conversely, overexpression of protective factors like coenzyme Q10 pathway components may mitigate inflammation.
How EDITGENE Supports positive regulation of cardiac muscle hypertrophy Research
Researchers studying positive regulation of cardiac muscle hypertrophy-related genes often need to determine whether a candidate gene is causally involved in driving or modulating cardiomyocyte growth. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic perturbations in cardiac cell models and animal models, accelerating target validation and therapeutic development.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cardiac muscle hypertrophy research.
Frequently Asked Questions About positive regulation of cardiac muscle hypertrophy
What is GO:0010613?
GO:0010613 is the Gene Ontology term for positive regulation of cardiac muscle hypertrophy, defined as any process that increases the rate, frequency, or extent of heart enlargement due to increased size of individual cardiac muscle fibers without cell division.
What genes are involved in positive regulation of cardiac muscle hypertrophy?
Key genes include DYRK1B, STAT3, LincRNA-p21, NLRP3, IL1β, HNMT, SMPD1, and CLU, among others, as identified in recent studies [2,3,4,5,6,8].
What is the difference between physiological and pathological cardiac hypertrophy?
Physiological hypertrophy is an adaptive, reversible response to exercise or pregnancy, while pathological hypertrophy is maladaptive, often caused by pressure overload or neurohormonal stress, and can lead to heart failure.
How is cardiac muscle hypertrophy regulated?
It is regulated by signaling pathways such as DYRK1B-STAT3, PI3K/Akt, MAPK, and calcineurin-NFAT, as well as noncoding RNAs and metabolic enzymes [1,2,3,5].
What diseases are associated with positive regulation of cardiac muscle hypertrophy?
Heart failure, diabetic cardiomyopathy, and myocardial infarction are major diseases linked to dysregulated hypertrophy [2,4,5,6,7].
What experimental models are used to study cardiac muscle hypertrophy?
Common models include transverse aortic constriction (TAC) in mice, high-fat diet-induced diabetic cardiomyopathy, and in vitro cardiomyocyte stretch or neurohormonal stimulation [2,3,6,7,8].
How can CRISPR be used to study cardiac hypertrophy?
CRISPR enables knockout, point mutation, knock-in, and overexpression of candidate genes in cardiomyocytes and animal models to establish causality and dissect mechanisms [2,3,5,8].
What is the role of DYRK1B in cardiac hypertrophy?
DYRK1B activates STAT3, impairs mitochondrial bioenergetics, and drives cardiac hypertrophy and heart failure; its inhibition is protective.
What is LincRNA-p21 and how does it affect hypertrophy?
LincRNA-p21 is a long noncoding RNA that promotes cardiac hypertrophy; its therapeutic inhibition protects against hypertrophy.
What is the role of mitophagy in cardiac hypertrophy?
Mitophagy is essential for maintaining cardiac function during stress; its impairment exacerbates diabetic cardiomyopathy and hypertrophy.
Conclusion
GO:0010613, positive regulation of cardiac muscle hypertrophy, is a central biological process that integrates mechanical, neurohormonal, metabolic, and inflammatory signals to drive cardiomyocyte growth. Understanding its molecular underpinnings is critical for developing therapies that promote adaptive hypertrophy or prevent maladaptive remodeling. The diverse regulators identified, from DYRK1B-STAT3 to LincRNA-p21 and metabolic enzymes, highlight the complexity of this process and the need for precise experimental models. EDITGENE's CRISPR services provide powerful tools to dissect these mechanisms and accelerate translational research.
References
- 1. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 2. Zhuang L et al.. 2022. DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics.. Circulation 145(11):829-846 PMID: 35235343
- 3. Wang Y et al.. 2024. Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy.. Circ Res 135(3):434-449 PMID: 38864216
- 4. Pan W et al.. 2024. Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway.. BMC Cardiovasc Disord 24(1):76 PMID: 38281937
- 5. Zhang J et al.. 2026. Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure.. Eur Heart J 47(19):2345-2363 PMID: 41568626
- 6. Wei Y et al.. 2025. Acid sphingomyelinase promotes diabetic cardiomyopathy via disruption of mitochondrial calcium homeostasis.. Cardiovasc Diabetol 24(1):272 PMID: 40640752
- 7. Tong M et al.. 2019. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy.. Circ Res 124(9):1360-1371 PMID: 30786833
- 8. Turkieh A et al.. 2024. Regulation of Clusterin in the Heart and Plasma of Mice After Transverse Aortic Constriction.. J Cell Mol Med 28(23):e70290 PMID: 39671261
